Literature DB >> 15655712

The role of GLP-1 in the life and death of pancreatic beta cells.

R Perfetti1, H Hui.   

Abstract

Glucagon-like peptide-1 (GLP-1), a peptide hormone produce by intestinal cells, has recently been shown to be capable of modulating islet cell mass. Administration of GLP-1 to rodent models of type 2 diabetes ameliorates insulin secretion, induces the replication of islet cells, and promotes islet-cell neogenesis from pancreatic ductal cells susceptible to transdifferentiate in insulin-producing cells. In addition, an anti-apoptotic effect of GLP-1 has been described in hyperglycemic animal models, using freshly isolated human islets or cultured beta cell lines exposed to various pro-apoptotic stimuli. The aim of this article is to review those reports that have emphasized the role of GLP-1 as a regulator of islet cell mass.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15655712     DOI: 10.1055/s-2004-826167

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  18 in total

Review 1.  The structure and function of the glucagon-like peptide-1 receptor and its ligands.

Authors:  Dan Donnelly
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Food protein-derived bioactive peptides in management of type 2 diabetes.

Authors:  Prasad Patil; Surajit Mandal; Sudhir Kumar Tomar; Santosh Anand
Journal:  Eur J Nutr       Date:  2015-07-08       Impact factor: 5.614

Review 3.  Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.

Authors:  Bo Ahrén
Journal:  World J Diabetes       Date:  2014-02-15

4.  Common Channel Length in Bypass Surgery Does Not Impact T2DM in Diabetic Zucker Rats.

Authors:  Claudia Laessle; Sven Michelmichel; Goran Marjanovic; Simon Kuesters; Gabriel Seifert; Ulrich T Hopt; Jodok Matthias Fink
Journal:  Obes Surg       Date:  2017-08       Impact factor: 4.129

5.  Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes?

Authors:  Bo Ahrén
Journal:  Curr Diab Rep       Date:  2011-04       Impact factor: 4.810

6.  New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.

Authors:  Baptist Gallwitz
Journal:  Rev Diabet Stud       Date:  2005-08-10

Review 7.  Beta-cell failure in type 2 diabetes mellitus.

Authors:  Cristina Lencioni; Roberto Lupi; Stefano Del Prato
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

8.  Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.

Authors:  Y Moritoh; K Takeuchi; T Asakawa; O Kataoka; H Odaka
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 9.  GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

Authors:  Bo Ahrén
Journal:  Curr Diab Rep       Date:  2007-10       Impact factor: 4.810

10.  TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.

Authors:  R Ito; Y Tsujihata; K Matsuda-Nagasumi; I Mori; N Negoro; K Takeuchi
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.